September 2025

Welcome to the Haematex Newsletter - September 2025

ADDITIONAL VALUE FOR HRRS USING THE APTT CORRECTION RATIO

Antihepca™-HRRS was originally developed to identify plasmas which may be accidentally contaminated with heparin or which have an unexpectedly prolonged APTT.  This reagent now seems to have additional potential value in testing (as shown by Stephen MacDonald from Cambridge).  Antihepca™- HRRS effectively shortens APTT and is a reliable indicator of heparin activity, leaving prolonged results in samples where haemostasis may be impaired. The APTT Correction Ratio with Antihepca™-HRRS correlates better with heparin activities than APTT alone, particularly with ATA. This approach not only improves the ability to monitor heparin but also permits detection of underlying conditions unrelated to heparin, thereby reducing potential bleeding risks.  

“The diagnostic significance of APTT tests and their correlation with heparin anti-Xa and anti-IIa activities is improved by pairing with a heparin-resistant recalcification solution (HRRS)”. Georgina Attrill, Stephen MacDonald, et al. J Clin Med. 2025.  https://www.preprints.org/manuscript/202507.1140/v1

Thanks also to the four major Australian labs who used HRRS (Antihepca™-HRRS (AHCA)) in a 2022 survey, the figure below shows unedited results. Each lab provided basic clinical information on their abnormal plasmas which allowed us to group the 55 results accordingly.  

It is apparent that all the heparin samples grouped together and could be easily distinguished from most of those which had some other reason for prolonged APTT.

HRRS was developed over a decade ago at Haematex Research in Sydney, today it is branded Antihepca™-HRRS for the EU market and it has IVDR regulatory clearance. Together with DOAC-Stop™, Haematex is innovating on the global stage and bringing efficiencies to coagulation labs. We are a proudly Australian owned small business, and we thank you for your support over the years.

FACTOR VIII and IX SENSITIVE APTT REAGENTS

In our previous newsletter, we introduced a new silica-based APTT reagent which delivers superior factor sensitivity, especially for low factors VIII and IX, while maintaining reliability in detecting coagulation defects. This reagent shows reduced interference from lupus anticoagulant, minimising unnecessary concerns in pre-surgical cases compared with Synthasil.  We have now updated our website with comprehensive product information https://www.haematex.com/products/sunbio-products.  Sunbio-Tech also has ellagic acid-based APTT reagents and indeed a full range of high quality/low cost coagulation diagnostics, instruments and consumables.

These reagents are currently RUO but if there is interest, we could apply for ARTG listing. For evaluations, we are happy to supply individual vials free of charge, please enquire for more information.

Haematex is the only Australian distributor which carries out local R&D into coagulation diagnostics. When you purchase from us, a portion of profits go towards projects such as our own locally made DOAC-Stop™, and research on dRVVT and lupus anticoagulants. We hope this newsletter has been of interest, if you do not wish to receive future updates, please let us know.

‍